Lyme disease caused by the Borrelia burgdorferi (Bb or B. burgdorferi) is a most common 28 vector-borne, multi-systemic disease in USA. Although, most Lyme disease patients can be 29 cured with a course of antibiotic treatment, a significant percent of patient population fail to be 30 disease-free post-treatment, necessitating the development of more effective therapeutics. We 31 previously found several drugs including disulfiram having with good activity against B. 32 burgdorferi. In current study, we evaluated the potential of repurposing the FDA approved 33 disulfiram drug for its borreliacidal activity. Our in vitro results indicate disulfiram shows 34 excellent borreliacidal activity against both the log and stationary phase B. burgdorferi. 35 Subsequent mice studies have determined that the disulfiram eliminated B. burgdorferi 36 completely from hearts and urinary bladder by day 28 post infection, demonstrating the practical 37 application and efficacy of disulfiram against B. burgdorferi in vivo. Moreover, disulfiram 38 treated mice showed reduced expression of inflammatory markers and protected against 39 histopathology and organ damage. Furthermore, disulfiram treated mice showed significantly 40 lower amounts of total antibody titers (IgM and IgG) at day 21 and total IgG2b at day 28 post 41 infection. Mechanistically, cellular analysis of lymph nodes revealed a decrease in percentage of 42 CD19+ B cells and increase in total percentage of CD3+ T cells, CD3+ CD4+ T helpers, and 43 naïve and effector memory cells in disulfiram-treated mice. Together, we demonstrate that 44 disulfiram has the potential and could be repurposed as an effective antibiotic for treating Lyme 45 disease in near future. 46 47 48 49 50 51
Introduction
explanations for symptoms in animal models could be B. burgdorferi adapting multiple immune 71 evasion mechanisms like alteration of highly immunogenic surface antigens 15, 16 , inhibition of 72 complement-mediated bacterial lysis 17,18 that may render antibody response ineffective, there by 73 supporting ongoing PTLDS. Therefore, based on these observations new mechanistic classes of 74 antibiotics need to be developed to treat infections raising from these resistant forms of B. 75 burgdorferi. 76
One approach to expedite the development of new antibiotics is to repurpose preexisting drugs 77 that have been approved for the treatment of other medical conditions. Previously, we screened 78 drugs (80% of them FDA approved, with a total of 4366 chemical compounds from four 79 different libraries) with high activity against the log and stationary phase of B. burgdorferi by 80
BacTiter-Glo™ Assay. Among them, disulfiram (Antabuse TM ), an oral prescription drug for the 81 treatment of alcohol abuse since 1949, was found to have the highest anti-persister activity 82 against B. burgdorferi 19 . In addition, disulfiram and its metabolites are potent inhibitors of 83 mitochondrial and cytosolic aldehyde dehydrogenases (ALDH) 20 . Recent U.S. clinical trials 84 using repurposed disulfiram treatments include: methamphetamine dependence (NCT00731133); 85 cocaine addiction (NCT00395850); melanoma (NCT00256230); muscle atrophy in pancreatic 86 cancer (NCT02671890); HIV infection (NCT01286259) modulator of amyloid precursor protein 87 processing (NCT03212599) and also recently initiated for previously treated Lyme disease 88 (NCT03891667) 21 . In the area of infectious disease, disulfiram has been shown have 89 antibacterial 22, 23 , and anti-parasitic 24 properties. Recently in a clinical setting, disulfiram appears 90 to have conferred benefit in the treatment of a limited number of patients with Lyme disease and 91 babesiosis 25 . Disulfiram is an electrophile that readily forms disulfides with thiol-bearing 92 substances. B. burgdorferi possess a diverse range of intracellular cofactors (e.g., coenzyme A 93 reductase) 26 , metabolites (e.g., glutathione), and enzymes (e.g., thioredoxin) 27 containing 94 thiophilic residues that disulfiram can potentially modify by thiol-disulfide exchange to evoke 95 antimicrobial effects. Therefore, disulfiram has potential to inhibit B. burgdorferi metabolism by 96 forming mixed disulfides with metal ions 28 and it has been shown by our group previously that 97 B. burgdorferi require zinc and manganese as co-factors for key biological processes 29 . 98
In the present study, we evaluated the antibacterial activities of disulfiram against log and 99 stationary phases of B. burgdorferi in more detail. Furthermore, bactericidal activity of 100 While our initial screen of disulfiram from four drug libraries is based on Bac titer-Glo assay 19 , 123
we performed our preliminary disulfiram study of varying concentrations ranging from (100 µM 124 to 0.625 µM) by Bac titer-Glo assay (Supplementary Figure 1A and (Figure 2A and 2B). In 142 our study also, as reported earlier 13 doxycycline was significantly able to reduce the viability of 143 log phase B. burgdorferi by ~90-97% compared to the control ( Fig. 1A and 1B ). However, 144 doxycycline treatment had no significant effect on the cells in the stationary phase cultures as 145 observed by increasing proportion of viable cells after antibiotic exposure compared to the 146 control ( Figure 2B and 2C). However, at high concentration (ranging from 50 µM-100 µM) lose 147 efficacy and shows reduced bactericidal activity with increase in concentration of disulfiram 148 drug in DMSO or cyclodextrin. These results are specific since treatment with ultra-pure water 149 or cyclodextrin or DMSO in BSK medium did not significantly reduce the viability of the 150 spirochete rich log phase culture and persisters rich stationary cultures compared to the control 151 observed in both direct dark field and SYBR Green-I /PI based fluorescent microscopy counting 152 respectively ( Fig. 1A and 2A ). 153
To validate our preliminary results, B. burgdorferi B31 log and stationary forms were further 154 evaluated in vitro for disulfiram in DMSO and disulfiram in cyclodextrin drugs sensitivity by a 155 fluorescent microscopy counting using SYBR Green-I (live cells stain green) and Propidium 156 Iodide (dead cells stain red). Consistently, the 5µm (1.48 µg/ml) concentration of disulfiram in 157 DMSO and disulfiram in cyclodextrin drugs significantly reduced log phase spirochetes by ~ 94 158 %, but in the remaining 6 % of the population, ~ 4 % were stained green for live while ~ 2 % 159 were stained red for dead ( Figure 2B ). While doxycycline significantly reduced the log phase 160 viability by ~ 97%, it did not reduce the stationary phase viability of B. burgdorferi ( Figure 2B to the concentration. However, the slope of the increase changed above 10 µM indicating a 179 critical aggregation concentration (CAC). The results from the CD preparation showed a non-180 linear trend with a break at 10 µM consistent with the CAC results from DMSO preparation. 181
Atomic force microscopy-based techniques helped us to further evaluate the small volume (10 182 µL) of liquid sample aliquots and fast drying of the highly spread droplets on hydrophilic 183 substrates allow to assess the real disulfiram particle dimensions with minimal contribution of 184 secondary sample aggregation due to local increase in its concentration due to drying. In 185 supplemental figure 2 observed that very few aggregates were formed for DMSO samples for all 186 concentrations (supplemental figure 2; E-H). The smaller particles are less than 1 nm in height.
For cyclodextran particles, we can see larger particles that are quite wide, but also quite flat -188 only 10 nm high, on average. These are likely particles formed due to sample drying. However, 189 for smaller particles, a crossover can be seen from 25 to 10 µM (supplemental figure 2; A-D). In 190 the former sample, we can still observe them (white arrows), but not in the latter, which is only 191 2.5 times less concentrated. Thus, this can be proof of sample aggregation, which starts to be 192 substantial only above 20 µM, as evident from our DLS data. Figure 3B ). Whereas in the doxycycline treatment (50 207 mg/kg) group, 3 out of 5 mice were positive by PCR from heart and ear tissues but none positive 208 for PCR from bladder tissues ( Figure 3B ). Similar results observed in cultured ear and heart 209 tissues of respective groups (data not shown). The disulfiram treatment group had statistically 210 significant lower number of B. burgdorferi compared to untreated infected controls (Table 2 and 211 Figure 3B ). On the other hand, in the day 21 post disulfiram treatment group, 2 out of 4 mice 212 were flaB gene PCR positive from ear and rest of the tissues heart and bladder were PCR 213 negative ( Figure 3B ). Whereas in the doxycycline treatment group, 4 out of 4 mice ears were 214 PCR positive and 1 out of 4 mice bladder was PCR positive but none positive for PCR from 215 heart ( Table 2 and Figure 3B ). Similar results observed in cultured ear and heart tissues of 216 respective groups (data not shown). These results showed an overall better efficacy in vivo 217 C3H/HeN mouse to restrict the further growth and dissemination of B. burgdorferi. 218
Disulfiram treatment decreases disease pathology and further reduces inflammatory 219 markers in the heart of B. burgdorferi infected C3H/HeN mice 220
In Lyme borreliosis, heavy inflammatory infiltrates dominated by mono or polymorphonuclear 221 leukocytes are typically found at lesion sites 32 . We performed histopathology analysis of heart in 222 both the day 14 and day 21 post disulfiram treatment group mice and found normal features of 223 aorta, valves and few to no mononuclear leukocytes inflammation in the myocardium which 224 signifies inactive carditis than the infected mice ( Figure 3C In infectious diseases, a hallmark of inflammatory tissue reactions is the recruitment and 231 activation of leukocytes. Chemo and cytokines play a pivotal role in mediating these events. We 232 further determined whether disulfiram treatment alters the inflammatory responses in the heart at 233 both day 14 and day 21 post infection, we evaluated B. burgdorferi induced myocardial 234 inflammation by quantification of mRNA transcription of CxCL1 (KC), CxCL2 (MIP-2), CCL5 235 (RANTES), TNFα, IFNγ, IL-10, IL-1β, iNOS and NOS-2 by qRT-PCR. In the day 14 post 236 disulfiram treatment group, levels of MIP-2, TNFα, IFNγ and IL-10 were significantly lower 237 (reached normal levels) relative to infected untreated mice ( Figure 4 ). More specifically, IL-10 238 levels were reduced to 60-fold ( Figure 4C 
Disulfiram treatment reduces antibody titers in the B. burgdorferi infected mouse 254
We next sought to determine whether disulfiram treatment affects antibody development during 255 day 14 and day 21 post B. burgdorferi infection, we measured the serum levels of each subtype 256 of total immunoglobulins using an ELISA. The results at day 21, showed that the total amount of 257 IgM and IgG levels were significantly lower in disulfiram treated mice compared infected 258 control mice ( Figure 5A ). Among the IgG subtypes, total IgG1 levels were significantly lower 259 than the infected control mice ( Figure 5A ). However, there was no effect on other IgG subtypes 260 like IgG2a, IgG2b and IgG3 ( Figure 5A ). While at day 28, only trend towards lower IgG levels 261 observed but were not statistically significant ( Figure 5B ). However, IgG2b levels were 262 significantly lower in disulfiram treated mice and no effect on other IgG subtypes like IgG1, 263
IgG2a and IgG3 ( Figure 5B ). Whereas doxycycline treatment group does not show any reduction 264 of antibody titers at day 21 and day 28 respectively ( Figures 5A & B) . These data suggest that 265 the disulfiram treatment might induced development of antibody subtypes very efficiently and 266 affect IgG class switching, which may represent a contributing factor in lowering B. burgdorferi 267 titers at day 21 and clearance of Bb more efficiently at day 28. However, we cannot exclude the 268 fact that there is a possibility that B cells expressing different immunoglobulin isotypes are 269 selectively expanded. Since antibiotics are the top-of-the-line options to treat infections, there remains a dire need and 296 a practical approach to bring more efficient antibiotics to clinic. The repurposing of FDA 297 approved antibiotics through fast-track approvals can be an excellent solution. In this current 298 study, we evaluated the borreliacidal potential of FDA approved drug disulfiram in vitro and in 299 vivo based on our previous high-throughput screening hits 19, 35 . We performed preliminary in Disulfiram is an oral medication that is approved by the U.S. Food and Drug Administration 315 (FDA) for administration of up to 500 mg daily 41 . Pharmacokinetic studies in humans has shown 316 that disulfiram has a half-life (t 1/2 ) of 7.3 h and a mean plasma concentration of 1.3 nM, although 317 significant intersubjective variations are noted 42 . The toxicity of both disulfiram and its 318 metabolites have also been broadly investigated in cell and animal studies, which yielded no 319 evidence for teratogenic, mutagenic, or carcinogenic effects 43 . DMSO proved to be low dose 320 toxic in vivo 44 so, we have used non-toxic cyclodextrin 45,46 as a solubilizing agent for 321 disulfiram in vivo studies. Based on these observations, we conducted our preliminary in vivo 322 mouse efficacy studies by administering (I.P) low dose of 10 mg/kg of body weight disulfiram to 323 infected C3H/HeN mice for 5 days and found that these mice could not able to clear the B. Macrophage phenotype is flexible, and once the infection is cleared and a more anti-346 inflammatory environment is created, these inflammatory cells may switch to a proresolution M2 347 phenotype 51 . Henceforth, in disulfiram treated mice since infection is cleared, M2 polarizing 348 factors like NOS2 (iNOS) were elevated than the doxycycline treated group and PBS infected 349 group at day 21 or day 28 post infection (Figure 4 ). However, underlying mechanism involved in 350 differential expression of chemo and cytokines and their effect on disease severity needs to be 351 investigated. 
Materials and Methods 389

Culturing and growth conditions of B. burgdorferi B31 390
Borrelia burgdorferi sensu stricto low passage strain B31 was (obtained from the American 391 Type Culture Collection Manassas, VA) used for MIC tests and all infection studies in C3H/HeN 392 mice. Bacteria cultures were started by thawing -80 0 C glycerol stocks of B. burgdorferi (titer, 393 6% rabbit serum followed by incubating at 33 0 C. After incubation for 4-5 days log phase, and 8-395 9 days stationary-phase B. burgdorferi culture (~10 6 borrelia/mL) was transferred into a 48-well 396 plate for evaluation with the drugs. 397
Drug formulations 398
The disulfiram (Sigma, USA) stock solution (50 mM) was made by dissolving in sterile 30% 399 were made similarly and it is important to note that the vehicle controls were identical to the test 407 formulation in every single aspect except for the active ingredient. This measure was strictly 408 followed for vehicle control wherever used in entire study. 409
In-vitro testing of antibiotics by BacTiter Glo® assay, microdilution and SYBR Green I/PI 410 assay methods 411
The MIC was determined by using Bac Titer-Glo microbial cell viability assay 29 . After 72 hours, 412 100 µL of culture was taken from each well and mixed with 100 µL of Bac Titer-Glo® reagent 413 (Promega, Madison, WI, USA). Then, the assay was performed according to the manufacturer's 414 instructions. Luminescence was measured on a CLARIOstar micro plate reader at an integration 415 time of 500 milliseconds. 416 A standard microdilution method was used to determine the minimum inhibitory concentration 417 (MIC) of the antibiotics tested 56 . Approximately, 1 × 10 6 B. burgdorferi were inoculated into 418 each well of a 48-well tissue culture microplate containing 900 μ L of BSK medium per well. The 419 cultures were then treated with 100 μ L of each drug at varying concentrations ranging from 420 0.625, 1.25, 2.5, 5, 10 and 20 μ M. Control cultures were treated with respective vehicles, and all 421 experiments were run in triplicate. The well plate was covered with parafilm and placed in the 422 33 0 C incubator with 5% CO 2 for 4 days. Spirochetes proliferation was assessed using a bacterial 423 counting chamber (Petroff-Hausser Counter) after the 4-5 days incubation followed by dark-field 424 and fluorescence microscopy. To further determine the minimum bactericidal concentration 425 (MBC) of the antibiotics tested (the minimum concentration beyond which no spirochetes can be 426 sub cultured after a 3-week incubation period), wells of a 48-well plate were filled with 1 mL of 427 BSK medium and 20 μ L of antibiotic-treated spirochetes were added into each of the wells. The 428 well plate was wrapped with parafilm and placed in the 33 0 C incubator with 5 % CO 2 for 3 429 weeks (21 days). After the incubation period, the plate was removed and observed for motile 430 spirochetes in the culture by dark-field and further cell proliferation was assessed using the 431 SYBR Green I/PI assay fluorescence microscopy. All these experiments were repeated at least 432 three times. Statistical analyses were performed using Student's t -test. 433
Dynamic light scattering 434
The stock solutions of 1M disulfiram was prepared either in DMSO or in 30% (w/v) 435 Total RNA was extracted from tissues using RNeasy mini kit (Qiagen, USA) and reverse 480 transcribed using a high-capacity cDNA reverse transcription kit (Invitrogen, USA). cDNA was 481 subjected to real-time PCR using primer and TAMRA probes (Stanford Protein and Nucleic acid 482 Facility) previously described 57 . PCR data are reported as the relative increase in mRNA transcript levels of CxCL1 (KC), CxCL2 (MIP-2), CCL5 (RANTES), IL-10, TNF-α, IFN-γ, 484 iNOS and NOS2 normalized to respective levels of GAPDH. 485
Histopathology 486
For histopathology, heart samples were fixed in 10% formalin buffer followed by staining of 487 vertical histological sections with hematoxylin and eosin dye. Heart tissues were assessed for 488 inflammation by microscopic examination at intermediate (10X), and high (40X)-power 489 magnification and were scored for severity of inflammation (carditis, vasculitis) according to the 490 percentage of inflammation at the heart base upon examination at low power (10X). Scores of 0 491 (none), 1 (minimal; less than 5%), 2 (mild; between 5% and 20%), 3 (moderate; between 20% 492 and 35%), 4 (marked; between 35% and 50%), and 5 (severe; greater than 50%) were assigned 493 for the severity of inflammation 58,31 . Myocarditis consisted of focal or diffuse interstitial 494 infiltrates of mononuclear leukocytes in the myocardium. The microscopic photographs were 495 captured on Olympus CX-41 microscope (Olympus, Tokyo, Japan). The images are shown at 496 10X and 40X magnification 497
Quantification of total Immunoglobulins in serum by ELISA 498
Quantification of total mouse immunoglobulin concentration IgA, IgM, IgG, IgG1, IgG2a, 499
IgG2b, and IgG3 in mouse serum was done using Ready-Set-Go ELISA kits (Invitrogen, USA). 500
Flow cytometry 501
Single cell suspensions of lymphoid tissues were prepared as described 57 , live/dead cell viability 502 stain was used to eliminate dead cells followed by single cells separation from doublets by FSC-503 A vs FSC-H plots. Cells were incubated in Fc blocking for 15 min at 4°C in staining buffer and 504 incubated with the appropriate marker for surface staining in the dark for 30 min at 4°C. Surface 505 lineage markers for T cells CD3, CD4, CD8, CD62L, CD44 and B cells was CD-19 conjugated with PercP Cy5.5 (Tonbo Biosciences) were described previously 57 . Cells were acquired on a 507 BD-LSR II flow cytometer and data analyzed using Flow Jo software. 508
Statistics 509
Data analysis was done using Graph Pad Prism software. Single comparisons within uninfected 510 or drug treated groups and infected groups were analyzed with two-tailed paired t-test, with 511 unpaired t-test with Welch's correction and with multiple t-tests. 
